# A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice

> **NCT05069545** · — · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 411 (actual)

## Conditions studied

- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Insulin degludec
- **DRUG:** Fast-acting insulin aspart

## Key facts

- **NCT ID:** NCT05069545
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-11
- **Primary completion:** 2024-09-10
- **Final completion:** 2024-09-10
- **Target enrollment:** 411 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05069545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05069545, "A Research Study Looking at How the Use of NovoPen® 6 for Treatment With Tresiba® & Fiasp® Affects the Blood Sugar Level in Patients With Type 1 Diabetes as Part of Local Clinical Practice". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05069545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*